In a report released on January 30, David Evans from Kepler Capital maintained a Hold rating on Sanofi (SNYNF – Research Report), with a price ...

Sanofi (NASDAQ:SNY – Get Free Report) was upgraded by stock analysts at Deutsche Bank Aktiengesellschaft from a “sell” rating to a “hold” rating in a report released on Thursday, Marketbeat Ratings ...

China NMPA approves Sanofi’s Sarclisa for patients with newly diagnosed multiple myeloma ineligible for transplant: Paris Saturday, February 1, 2025, 12:00 Hrs [IST] The Nationa ...

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus. Lantus cost $292 for a 30-day supply. Drugmaker Viatris launched two versions ...

President Trump has said he plans to raise or impose new tariffs on a wide range of products, including pharmaceuticals. While Trump has openly discussed rolling out tariffs on China, Mexico and ...

US pharma major AbbVie has posted financial results for the fourth quarter and full year ended December 31, 2024, that pleased investors and sending the firm’s shares up 7.8% to $189.19 by mid-morning ...

Japanese drugmaker Daiichi Sankyo has appointed Hiroyuki Okuzawa to succeed Sunao Manabe, as chief executive (CEO), effective April 1, 2025.

Tractor Supply (NASDAQ:TSCO – Get Free Report)‘s stock had its “outperform” rating restated by Telsey Advisory Group in a report released on Thursday,Benzinga reports. They presently have a $67.00 ...

Organ Transplantation Immunosuppressive Drug Market. Global Organ Transplantation Immunosuppressive Drug market presents significant growth opportunities.

Sarclisa (isatuximab) has been approved in China for use in combination with the VRd regimen to treat newly diagnosed multiple myeloma patients w ...

Sanofi (NASDAQ:SNY – Get Free Report) has been given a consensus recommendation of “Buy” by the three brokerages that are presently covering the stock, Marketbeat.com reports. One investment analyst ...